Design and synthesis of piperazinylpyrimidinones as novel selective 5-HT2C agonists

This Letter reports the design and synthesis of several novel series of piperazinyl pyrimidinones as 5-HT_2C agonists. Several of the compounds presented exhibit good in vitro potency and selectivity over the closely related 5-HT_2A and 5-HT_2B receptors. Compound 11 was active in in vivo models of stress urinary incontinence.     

Discovery of a new series of 5-HT1A receptor agonists

Starting from compounds previously identified as α₁-adrenoceptor antagonists that were also found to bind to the 5-HT_1A receptor, in an attempt to separate the two activities, a new series of 5-HT_1A receptor agonists was identified and shown to have high potency and/or high selectivity. Of these, compound 13, which combines high selectivity (5-HT_1A/α₁ = 151) and good agonist potency (pD₂ = 7.82; E_max = 76), was found to be the most interesting.     

Arylpiperazine-containing pyrrole 3-carboxamide derivatives targeting serotonin 5-HT2A, 5-HT2C,and the serotonin transporter as a potential antidepressant

Arylpiperzine-containing pyrrole 3-carboxamide derivatives were synthesized and evaluated as novel antidepressant compounds. The various analogues were efficiently prepared and bio-assayed for binding to 5-HT_2A, 5-HT_2C receptor, and 5-HT transporter. Based on their in vitro and in vivo activities as well as selectivity over other neurotransmitter receptors and PK profiles, 33 and 34 were identified as lead compounds. Consequently, this pyrrole series of compounds appears to be promising enough to warrant further investigation.     

Structural manipulation of aporphines via C10 nitrogenation leads to the identification of new 5-HT7AR ligands

Aporphine alkaloids containing a C10 nitrogen motif were synthesized and evaluated for affinity at 5-HT_1AR, 5-HT_2AR, 5-HT₆R and 5-HT_7AR. Three series of racemic aporphines were investigated: 1,2,10-trisubstituted, C10 N-monosubstituted and compounds containing a C10 benzofused aminothiazole moiety. The 1,2,10-trisubstituted series of compounds as a group displayed modest selectivity for 5-HT_7AR and also had moderate 5-HT_7AR affinity. Compounds from the C10 N-monosubstituted series generally lacked affinity for 5-HT_2AR and 5-HT₆R and showed strong affinity for 5-HT_1A or 5-HT_7AR. Compounds in this series that contained an N6-methyl group were up to 27-fold selective for 5-HT_7AR over 5-HT_1AR, whereas compounds with an N6-propyl substituent showed a reversal in this selectivity. The C10 benzofused aminothiazole analogues showed a similar binding profile as the C10 N-monosubstituted series i.e. strong affinity for 5-HT_1AR or 5-HT_7AR, with selectivity between the two receptors being similarly influenced by N6-methyl or N6-propyl substituents. Compounds 29 and 34a exhibit high 5-HT_7AR affinity, excellent selectivity versus dopamine receptors and function as antagonists in 5-HT_7AR cAMP-based assays. Compounds 29 and 34a have been identified as new lead molecules for further tool and pharmaceutical optimization.     

Discovery of a novel azepine series of potent and selective 5-HT2C agonists as potential treatments for urinary incontinence

A range of heterocycle fused azepines were synthesized in order to find a CNS penetrant, selective 5-HT_2C agonist for the treatment of incontinence. The pyridazo-azepines such as compound 11 were shown to be potent 5-HT_2C agonists and have potential for CNS penetration and good in vitro ADME properties but lacked selectivity against 5-HT_2B. Fusing a further heterocycle gave the selective triazolopyrimido-azepines. An example of this series, compound 36, was shown to be potent, selective, metabolically stable in vitro and efficacious in an in vivo model of stress urinary incontinence.     

6-Alkoxyisoindolin-1-one based dopamine D2 partial agonists as potential antipsychotics

A series of 6-alkoxyisoindolin-1-ones with a magic shotgun pharmacological profile are presented as potential antipsychotics. The in vitro pharmacological profile includes D₂ partial agonism (30–55%), 5-HT_1A partial agonism (60–90%), and 5-HT_2A antagonism. Selected compounds in this series displayed good in vivo activity and potency.     

Design and synthesis of pyridazinone-based 5-HT2C agonists

The SAR of a series of pyridazinone derived 5-HT_2C agonists has been explored and resulted in identification of a compound with excellent levels of 5-HT_2C functional agonism and selectivity over 5-HT_2A and 5-HT_2B. This compound displayed good in vivo efficacy in pre-clinical models of stress urinary incontinence, despite having physiochemical properties commensurate with impaired CNS penetration.     

Studies on a series of potent,orally bioavailable, 5-HT1 receptor ligands—Part II

A series of 5-(piperidinylethyloxy)quinoline 5-HT₁ receptor ligands have been studied by elaboration of the series of dual 5-HT₁-SSRIs reported previously. These new compounds display a different in vitro pharmacological profile with potent affinity across the 5-HT_1A, 5-HT_1B and 5-HT_1D receptors and selectivity against the serotonin transporter. Furthermore, they have improved pharmacokinetic profiles and CNS penetration.     

Synthesis and biological evaluation of (phenylpiperazinyl-propyl)arylsulfonamides as selective 5-HT2A receptor antagonists

A novel series of 5-HT_2A ligands that contain a (phenylpiperazinyl-propyl)arylsulfonamides skeleton was synthesized. Thirty-seven N-(cycloalkylmethyl)-4-methoxy-N-(3-(4-arylpiperazin-1-yl)propyl)-arylsulfonamide and N-(4-(4-arylpiperazin-1-yl)butan-2-yl)-arylsulfonamide compounds were obtained. The binding of these compounds to the 5-HT_2A, 5-HT_2C, and 5-HT₇ receptors was evaluated. Most of the compounds showed IC₅₀ values of less than 100 nM and exhibited high selectivity for the 5-HT_2A receptor. Among the synthesized compounds, 16a and 16d showed good affinity at 5-HT_2A (IC₅₀ = 0.7 nM and 0.5 nM) and good selectivity over 5-HT_2C (50–100 times) and 5-HT₇ (1500–3000 times).     

7-Sulfonamido-3-benzazepines as potent and selective 5-HT2C receptor agonists: Hit-to-lead optimization

New 7-sulfonamido-3-benzazepines 3 are disclosed as 5-HT_2C receptor agonists. Appropriate substitution of the amino group (R¹R²N–) gave compounds that were potent 5-HT_2C agonists with minimal activation of the 5-HT_2A and 5-HT_2B receptors. Furthermore, representative examples had excellent in vitro ADME properties and good selectivity over ion channel activity.